Keen Vision Acquisition Corporation Ordinary Shares KVAC
11.51 USD 0.00 (+0.00%)
At closeJul 31, 2026, 4:00 PM EDT
12.18 +0.67 +5.82%
After hours · Jul 31, 4:00 PM ET
11.51 Day range 12.00
52-week range unavailable
- YTD
- -2.04%
- 1 year
- +1.05%
News
defenseworld.net Financial Comparison: Blaize (NASDAQ:BZAI) and Keen Vision Acquisition (NASDAQ:KVAC) Blaize (NASDAQ: BZAI - Get Free Report) and Keen Vision Acquisition (NASDAQ: KVAC - Get Free Report) are both small-cap financial services companies, but which is the better business? We will compare…
defenseworld.net Keen Vision Acquisition (NASDAQ:KVAC) Shares Up 0.9% – Here’s What Happened Keen Vision Acquisition Corporation (NASDAQ: KVAC - Get Free Report)'s share price shot up 0.9% on Monday. The company traded as high as $12.00 and last traded at $12.1090. 69 shares changed hands…
defenseworld.net 65,256 Shares in Keen Vision Acquisition Corporation $KVAC Acquired by Crossingbridge Advisors LLC Crossingbridge Advisors LLC acquired a new stake in Keen Vision Acquisition Corporation (NASDAQ: KVAC) during the undefined quarter, according to the company in its most recent filing with the…
defenseworld.net Keen Vision Acquisition (NASDAQ:KVAC) Stock Price Up 0.1% – Time to Buy? Keen Vision Acquisition Corporation (NASDAQ: KVAC - Get Free Report)'s share price traded up 0.1% during mid-day trading on Friday. The company traded as high as $11.83 and last traded at $11.83. 73…
defenseworld.net Keen Vision Acquisition (NASDAQ:KVAC) Trading 0.5% Higher – Still a Buy? Keen Vision Acquisition Corporation (NASDAQ: KVAC - Get Free Report) shares traded up 0.5% during mid-day trading on Friday. The company traded as high as $11.63 and last traded at $11.63. 500 shares…
globenewswire.com Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025 BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation…
globenewswire.com Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation…
globenewswire.com Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation…
globenewswire.com Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of…
globenewswire.com Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a…
globenewswire.com Medera's Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht Cutting-Edge Cardiac Research: Novoheart's CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac…
globenewswire.com Medera, Inc. to Participate in Two Upcoming Investor Conferences SUMMIT, N.J. and BOSTON, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate in the two…
prnewswire.com Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs Human-specific diseases…
prnewswire.com Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all…
prnewswire.com STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Keen Vision Acquisition Corp. - KVAC NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS…
prnewswire.com Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with…
prnewswire.com Keen Vision Acquisition Corporation Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing September 15, 2023 SUMMIT, N.J., Sept. 14, 2023 /PRNewswire/ -- Keen Vision Acquisition Corporation ("KVAC") announced today that, commencing September 15, 2023, holders of the units sold in the Company's initial…